As on Wednesday, Allogene Therapeutics Inc (NASDAQ: ALLO) got off with the flyer as it spiked 5.67% to $1.49, before settling in for the price of $1.41 at the close. Taking a more long-term approach, ALLO posted a 52-week range of $0.86-$3.78.
It was noted that the giant of the Healthcare sector posted annual sales growth of 6.26% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 6.26%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 28.42%. This publicly-traded company’s shares outstanding now amounts to $223.16 million, simultaneously with a float of $160.22 million. The organization now has a market capitalization sitting at $334.85 million. At the time of writing, stock’s 50-day Moving Average stood at $1.3356, while the 200-day Moving Average is $1.2906.
Allogene Therapeutics Inc (ALLO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Allogene Therapeutics Inc’s current insider ownership accounts for 28.71%, in contrast to 50.55% institutional ownership. According to the most recent insider trade that took place on Nov 17 ’25, this organization’s SVP, Chief Technical Officer sold 786 shares at the rate of 1.22, making the entire transaction reach 959 in total value, affecting insider ownership by 217,721.
Allogene Therapeutics Inc (ALLO) Earnings and Revenue Records
Allogene Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 28.42% and is forecasted to reach -0.89 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 14.00% through the next 5 years, which can be compared against the 6.26% growth it accomplished over the previous five years trading on the market.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Let’s observe the current performance indicators for Allogene Therapeutics Inc (ALLO). It’s Quick Ratio in the last reported quarter now stands at 8.19.
In the same vein, ALLO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.98, a figure that is expected to reach -0.23 in the next quarter, and analysts are predicting that it will be -0.89 at the market close of one year from today.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Through scrutinizing the latest numbers posted by the [Allogene Therapeutics Inc, ALLO], it can be observed that its last 5-days Average volume of 3.45 million was lower the volume of 3.55 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 55.51% While, its Average True Range was 61.87.
Raw Stochastic average of Allogene Therapeutics Inc (ALLO) in the period of the previous 100 days is set at 85.98%, which indicates a major rise in contrast to 73.58% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.0951 that was higher than 0.0850 volatility it exhibited in the past 100-days period.
